Liquid Biopsy For Cancer Diagnostics Market Valuation Expected To Reach $19.32 Billion By 2029, Growing At A Rate Of 15.7%
Discover trends, market shifts, and competitive outlooks for the liquid biopsy for cancer diagnostics industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
How Has the Liquid Biopsy For Cancer Diagnostics Market Growth Performance Trended Historically, And What Lies Ahead?
In recent times, the market size for liquid biopsy in cancer diagnostics has seen swift growth. The projections show that it will increase from $9.23 billion in 2024 to $10.78 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 16.8%. The significant growth in the past can be related to the progress in genomic studies, escalating awareness about the perks of liquid biopsy, rising incidence of cancer, a surge in the requirement for non-invasive cancer diagnosis, and the broadening of precision medicine initiatives.
The market for liquid biopsy in cancer diagnostics is predicted to witness rapid growth in the upcoming years, reaching $19.32 billion by 2029 with a compound annual growth rate (CAGR) of 15.7%. The acceleration during the forecast period can be credited to the incorporation of liquid biopsy in standard cancer diagnostics, the utilization of liquid biopsy in detecting cancer early, the broadening of cancer screening programs, an intensified emphasis on personalized medicine in oncology, and augmented financing for liquid biopsy research. Emerging trends during the forecast period comprise the development of multi-omics liquid biopsy methods, the inclusion of artificial intelligence in liquid biopsy analysis, the expansion of liquid biopsy applications beyond oncology, the creation of blood-based biomarkers for cancer, and the customization of liquid biopsy assays designed for specific types of cancer.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12205&type=smp
Which Factors and External Forces Are Driving Demand in the Liquid Biopsy For Cancer Diagnostics Market?
The liquid biopsy for cancer diagnostics market is set to grow due to the increasing prevalence of cancer. Cancer, a group of diseases characterized by the uncontrolled proliferation and spread of abnormal cells to other organs or nearby tissues, necessitates diagnostic procedures such as early or recurring tumor detection, patient-specific risk evaluation, and treatment monitoring. The liquid biopsy method provides comprehensive and current data about tumor cell changes, therapeutic targets, and treatment resistance mechanisms by capturing the entirety of the disease, as it traces tumor cells or their byproducts released from all metastatic or primary tumor locations. As reported by the National Cancer Institute, a US-based government body, in May 2024, approximately 18.1 million people in the US had survived cancer. This number is anticipated to climb to 22.5 million by 2032. It is predicted that, by 2040, new cancer cases will increase to an annual figure of 29.9 million, while cancer-related deaths are expected to rise to 15.3 million. Thus, the escalating prevalence of cancer is fuelling the growth of the liquid biopsy for cancer diagnostics market.
Which Segments in the Liquid Biopsy For Cancer Diagnostics Offer the Most Growth?
The liquid biopsy for cancer diagnostics market covered in this report is segmented –
1) By Type: Product, Services
2) By Sample: Blood, Urine, Saliva
3) By Cancer: Lung Cancer, Breast Cancer, Colon Cancer, Other Cancers
4) By End-User: Hospitals, Diagnostic Centers, Other End-Users
Subsegments:
1) By Product: Circulating Tumor Cells (CTCs) Detection Kits, Circulating Tumor DNA (ctDNA) Detection Kits, Exosome Isolation Kits, Sample Collection Devices
2) By Services: Testing Services, Analytical Services, Bioinformatics Services
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=12205&type=smp
What Are the Fastest-Growing Geographies in the #Which Factors and External Forces Are Driving Demand in the Liquid Biopsy For Cancer Diagnostics Market?# Market?
North America was the largest region in the liquid biopsy for cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the liquid biopsy for cancer diagnostics market report during the forecast period. The regions covered in the liquid biopsy for cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Cutting-Edge Market Trends Are Expected to Drive theLiquid Biopsy For Cancer Diagnostics Market’s Growth?
Emergence of product innovations is a significant trend observed in the liquid biopsy for cancer diagnostics market. To solidify their presence in the market, key companies in this sector are focusing their efforts on developing innovative products. Take for example BostonGene, a biomedical software company based in the US. In June 2023, they rolled out new liquid biopsy solutions for the detection of clinically significant gene changes. This expanded testing portfolio is expected to accelerate the development of new assays, analytical instruments, and procedures for delivering precision medicine to patients. These solutions will leverage a variety of AI-powered molecular and immunological profiling techniques to assess tumors, microenvironments, and host immunity. Furthermore, it aids immunotherapy treatment, provides information on a patient’s immune-associated conditions, and tracks the progression of the disease and response to treatment.
View the full report here:
What Are the Key Elements That Define the Liquid Biopsy For Cancer Diagnostics Market?
Liquid biopsy for cancer diagnostics is a less invasive method than traditional tissue biopsies, which include evaluating genetic material or biomarkers discovered in a patient’s blood or other bodily fluids to find and monitor the presence of cancer. It is commonly used for screening and identifying non-small cell lung cancer (NSCLC) and as a gastrointestinal and ovarian liquid biopsy for cancer diagnostics.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12205
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
